Approved indications: Fasenra is FDA‑approved as an add‑on maintenance treatment for severe asthma with an eosinophilic phenotype in adults and children 6 years and older, and for the treatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGPA); it is not for relief of sudden breathing problems or status asthmaticus.

Off‑label uses: Clinicians sometimes use benralizumab off‑label for other eosinophil‑driven diseases such as hypereosinophilic syndromes or chronic rhinosinusitis with nasal polyps, but these uses rely mainly on small clinical trials and case reports, and the drug is not FDA‑approved for these conditions.

Efficacy in severe eosinophilic asthma: In clinical studies, Fasenra markedly reduced blood eosinophil counts, cut annual asthma exacerbations by roughly half versus placebo when added to standard therapy, and allowed some patients to lower oral steroid doses; many people notice improved asthma control within 4 to 8 weeks, with full benefit often assessed after about 3 to 4 months.

Efficacy in EGPA: In adults with relapsing or refractory EGPA, Fasenra given every 4 weeks led to remission in a substantial proportion of patients over about 9 to 12 months and enabled meaningful reductions in oral corticosteroid use, with efficacy generally comparable to mepolizumab in head‑to‑head study.

Comparison to similar drugs: Compared with other anti‑IL‑5 pathway biologics (such as mepolizumab or reslizumab), Fasenra offers similarly strong eosinophil depletion and exacerbation reduction, with the advantage of less frequent dosing (every 8 weeks for asthma maintenance after loading) and a safety profile that is broadly similar across the class.

Typical dosing for asthma: For adults and adolescents 12 years and older with severe eosinophilic asthma, the usual dose is 30 mg given by subcutaneous injection every 4 weeks for the first 3 doses, then once every 8 weeks. For children 6 to 11 years old, dosing is weight‑based: 10 mg if under 35 kg or 30 mg if 35 kg or more, every 4 weeks for the first 3 doses and then every 8 weeks.

Typical dosing for EGPA: For adults with eosinophilic granulomatosis with polyangiitis, the recommended dose is 30 mg by subcutaneous injection once every 4 weeks on an ongoing basis.

How it is given: Fasenra is injected under the skin of the thigh or abdomen by the patient or caregiver after training; the upper arm is an option when a healthcare provider or caregiver gives the injection. It can be given at any time of day, with or without food, using either a prefilled syringe or an autoinjector pen after the medicine has warmed to room temperature and been visually checked.

Special dosing instructions: Fasenra is used in addition to, not instead of, usual asthma or EGPA medicines, and controller inhalers or oral steroids should only be reduced gradually under medical supervision. Patients should continue to carry and use their rescue inhaler for sudden asthma symptoms because Fasenra does not work fast enough for emergencies.

Missed dose guidance: If a dose is missed, the patient should contact their healthcare provider as soon as possible for instructions rather than injecting late on their own schedule; the provider may reschedule the dose and adjust the calendar if needed.

Overdose: There is no specific antidote for taking too much Fasenra; suspected overdose should prompt calling a healthcare provider, poison control center, or emergency services, and treatment is supportive with monitoring for side effects or allergic reactions.

Common side effects: The most frequent side effects are headache and sore throat, and some people also experience mild injection‑site reactions (pain, redness, itching, or small lumps); these effects usually start within a day or two of injection, are generally mild to moderate, and often lessen over time.

Serious or rare adverse effects: Serious allergic (hypersensitivity) reactions, including anaphylaxis, angioedema, rash, hives, breathing difficulty, dizziness, or fainting, can occur hours to days after an injection and require immediate emergency care and permanent discontinuation of the drug. Because eosinophils may help fight certain parasitic worm (helminth) infections, untreated or resistant helminth infections should be managed and may require holding Fasenra until the infection is resolved.

Warnings and precautions: Fasenra must not be used in anyone with a known severe allergy to benralizumab or any component of the product. It should not be used to treat sudden asthma attacks or acute worsening of breathing, and existing inhaled or oral steroids should not be stopped or reduced abruptly without medical supervision. Data in pregnancy and breastfeeding are limited; as an IgG antibody, benralizumab can cross the placenta especially in the third trimester, so use is based on weighing disease control against uncertain fetal risk. It is not approved for asthma in children under 6 years or for EGPA in people under 18 years. No specific dose adjustments are recommended for kidney or liver impairment, but patients with significant organ disease should be monitored carefully.

Overall safety profile: Fasenra is not broadly immunosuppressive and has not been associated with increased rates of common infections in trials, so its overall safety profile is generally favorable compared with long‑term high‑dose oral corticosteroids, although long‑term data for rare events continue to accumulate.

Side effect reporting and safety updates: Patients in the U.S. can report suspected side effects to the FDA MedWatch program (by phone or online) or to the manufacturer, and up‑to‑date safety communications are available on the FDA and official Fasenra websites; any new or worsening symptoms should be promptly discussed with a healthcare professional.

Drug and supplement interactions: Because Fasenra is a monoclonal antibody degraded by normal protein‑breakdown pathways and not by liver enzymes such as CYP450, it is not expected to have significant pharmacokinetic interactions with most prescription drugs, over‑the‑counter medicines, or supplements, and it is routinely used alongside standard asthma and EGPA therapies (inhaled steroids, long‑acting bronchodilators, leukotriene modifiers, and oral steroids).

Other medicines, foods, and alcohol: No consistent interactions have been reported with common foods, alcohol, vitamins, or herbal products, though some interaction checkers list potential interactions with certain biologic cancer or immune therapies, so patients should always review their full medication and supplement list with their prescriber or pharmacist. Alcohol does not appear to interact directly but may worsen overlapping side effects like headache.

Health conditions and precautions: The main condition needing special attention is current or suspected parasitic (helminth) infection, which should be treated before starting Fasenra; if such an infection develops and does not respond to therapy while on Fasenra, the biologic may need to be paused until the infection clears. People with a history of severe allergic reaction to benralizumab must not receive it, and caution is advised in patients with significant chronic infections or immunologic disorders even though broad immunosuppression has not been seen.

Monitoring needs: At and after injections, healthcare providers typically monitor for allergic reactions and overall asthma or EGPA control, and may periodically check blood eosinophil counts and oral steroid doses to gauge response. Patients should promptly report any unusual infections, fevers, new rashes, or worsening breathing so therapy and monitoring can be adjusted.

Q: What is Fasenra used for?
A: Fasenra is used as an add‑on biologic treatment for severe asthma with an eosinophilic phenotype in people 6 years and older and for eosinophilic granulomatosis with polyangiitis (EGPA) in adults; it is not a rescue inhaler for sudden symptoms.

Q: How long does it take Fasenra to start working?
A: Blood eosinophil levels usually drop quickly after the first injection, but most people notice better asthma or EGPA control over several weeks, with full benefit typically assessed after about 3 to 4 months of regular dosing.

Q: Can I give Fasenra to myself at home?
A: Many patients use a prefilled syringe or Fasenra Pen at home once a healthcare provider has trained them on storage, preparation, and injection technique; some people continue to receive injections at a clinic if preferred or if home use is not appropriate.

Q: Do I still need my other asthma or EGPA medications?
A: Yes, Fasenra is added to your existing treatment plan, and inhalers or oral steroids should only be changed under medical supervision; never stop a steroid or controller inhaler suddenly just because you started Fasenra.

Q: Is Fasenra an immunosuppressant like chemotherapy or high‑dose steroids?
A: Fasenra specifically targets eosinophils and has not been shown to cause broad immune suppression like chemotherapy or long‑term high‑dose steroids, though it can slightly affect how your body handles certain parasitic infections and still carries a risk of allergic reactions.

Q: What if I am pregnant, planning pregnancy, or breastfeeding?
A: There is limited experience with Fasenra in pregnancy and breastfeeding, so decisions are individualized; you and your clinician will weigh the risks of uncontrolled asthma or EGPA against the limited safety data, and a pregnancy registry is available to track outcomes in exposed pregnancies.

Storage: Keep Fasenra in its original carton in the refrigerator at 36°F to 46°F (2°C to 8°C), do not freeze, shake, or expose it to heat, and protect it from light. If needed, a prefilled syringe or pen can be kept at room temperature (68°F to 77°F / 20°C to 25°C) for up to 14 days; once kept at room temperature it must be used within 14 days and should not be put back in the refrigerator.

Before use: When injecting at home, take the syringe or pen out of the refrigerator and let it warm to room temperature for about 30 minutes, and only use it if the solution is clear to slightly yellow without large particles and the product is not expired or damaged.

Disposal: After each injection, place the used syringe or pen immediately into an FDA‑cleared sharps disposal container or a heavy-duty, puncture‑resistant household container with a tight, puncture‑resistant lid; do not throw loose needles or pens into household trash or recycling, and follow local or pharmacist guidance for disposal of full sharps containers and any unused or expired medicine.